Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Farther Finance Advisors LLC

Farther Finance Advisors LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 39.4% during the third quarter, Holdings Channel reports. The fund owned 137 shares of the medical research company’s stock after selling 89 shares during the quarter. Farther Finance Advisors LLC’s holdings in Charles River Laboratories International were worth $27,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CRL. Boston Trust Walden Corp grew its holdings in shares of Charles River Laboratories International by 2.8% during the second quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company’s stock worth $41,381,000 after buying an additional 5,375 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in Charles River Laboratories International by 5.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 56,840 shares of the medical research company’s stock worth $15,401,000 after buying an additional 2,739 shares during the period. Natixis purchased a new stake in Charles River Laboratories International during the first quarter worth approximately $1,058,000. Tidal Investments LLC grew its stake in Charles River Laboratories International by 99.8% during the first quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company’s stock worth $1,435,000 after buying an additional 2,646 shares during the period. Finally, Epoch Investment Partners Inc. lifted its position in shares of Charles River Laboratories International by 2,733.4% during the first quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock worth $67,060,000 after purchasing an additional 238,766 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $187.74 on Friday. The firm has a 50-day moving average price of $195.26 and a 200 day moving average price of $207.52. The firm has a market capitalization of $9.60 billion, a PE ratio of 23.50, a P/E/G ratio of 5.33 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the prior year, the firm posted $2.72 EPS. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its board has approved a share repurchase plan on Wednesday, August 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 9.6% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

CRL has been the topic of a number of recent research reports. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Bank of America cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their price target for the company from $250.00 to $215.00 in a report on Wednesday, October 2nd. Evercore ISI upped their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. UBS Group increased their target price on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, CLSA raised shares of Charles River Laboratories International from an “underperform” rating to a “hold” rating and set a $205.00 target price on the stock in a report on Thursday, November 7th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $217.54.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).